Aduro Biotech, Inc. (NASDAQ:ADRO) EVP Dirk G. Brockstedt sold 1,815 shares of the business’s stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $8.01, for a total transaction of $14,538.15. Following the completion of the sale, the executive vice president now owns 75,533 shares of the company’s stock, valued at $605,019.33. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Aduro Biotech, Inc. (NASDAQ ADRO) traded up $0.30 during trading hours on Tuesday, reaching $8.25. 824,100 shares of the company were exchanged, compared to its average volume of 402,670. Aduro Biotech, Inc. has a 52 week low of $6.01 and a 52 week high of $15.52.

Aduro Biotech (NASDAQ:ADRO) last posted its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported ($0.33) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.03). Aduro Biotech had a negative net margin of 548.92% and a negative return on equity of 39.28%. The firm had revenue of $3.79 million for the quarter, compared to the consensus estimate of $4.04 million. During the same quarter in the prior year, the company earned ($0.54) earnings per share. The company’s quarterly revenue was up .0% compared to the same quarter last year. equities analysts anticipate that Aduro Biotech, Inc. will post -1.28 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This story was published by American Banking News and is owned by of American Banking News. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/11/14/aduro-biotech-inc-adro-evp-dirk-g-brockstedt-sells-1815-shares.html.

A number of large investors have recently bought and sold shares of ADRO. Legal & General Group Plc raised its holdings in Aduro Biotech by 11.2% in the 2nd quarter. Legal & General Group Plc now owns 10,359 shares of the biotechnology company’s stock worth $118,000 after purchasing an additional 1,043 shares in the last quarter. American International Group Inc. raised its holdings in Aduro Biotech by 7.1% in the 1st quarter. American International Group Inc. now owns 21,840 shares of the biotechnology company’s stock worth $235,000 after purchasing an additional 1,447 shares in the last quarter. Parametric Portfolio Associates LLC raised its holdings in Aduro Biotech by 15.9% in the 1st quarter. Parametric Portfolio Associates LLC now owns 15,424 shares of the biotechnology company’s stock worth $166,000 after purchasing an additional 2,119 shares in the last quarter. Voya Investment Management LLC raised its holdings in Aduro Biotech by 15.3% in the 2nd quarter. Voya Investment Management LLC now owns 18,935 shares of the biotechnology company’s stock worth $216,000 after purchasing an additional 2,515 shares in the last quarter. Finally, Nationwide Fund Advisors raised its holdings in Aduro Biotech by 12.5% in the 2nd quarter. Nationwide Fund Advisors now owns 23,112 shares of the biotechnology company’s stock worth $263,000 after purchasing an additional 2,567 shares in the last quarter. Institutional investors own 33.63% of the company’s stock.

A number of equities research analysts have recently weighed in on the stock. BidaskClub lowered shares of Aduro Biotech from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Zacks Investment Research lowered shares of Aduro Biotech from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. HC Wainwright set a $18.00 price objective on shares of Aduro Biotech and gave the stock a “buy” rating in a report on Wednesday, November 1st. Canaccord Genuity set a $30.00 price objective on shares of Aduro Biotech and gave the stock a “buy” rating in a report on Thursday, August 3rd. Finally, William Blair restated an “outperform” rating on shares of Aduro Biotech in a report on Monday, October 2nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the stock. Aduro Biotech has a consensus rating of “Buy” and a consensus target price of $19.14.

About Aduro Biotech

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Insider Buying and Selling by Quarter for Aduro Biotech (NASDAQ:ADRO)

Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.